CT
CTNM.US Contineum Therapeutics, Inc. Class A Common Stock
- Market cap
- USD 387M
- P/E
- -
- P/B
- 1.57x
- ROE
- -26.2%
- Dividend yield
- -
- Fundamental score
- -
Ratios use the latest price and the current fiscal year annualized from 3 quarters up to Sep 2026.
Is CTNM.US undervalued?
Graham numberThe Graham number of Contineum Therapeutics, Inc. Class A Common Stock cannot be estimated reliably (it needs positive earnings and book value).
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
Contineum Therapeutics, Inc. Class A Common Stock fundamental analysis
No fundamental analysis for Contineum Therapeutics, Inc. Class A Common Stock yet.
Contineum Therapeutics, Inc. Class A Common Stock stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About Contineum Therapeutics, Inc. Class A Common Stock
Contineum Therapeutics, Inc., a clinical stage biopharmaceutical company, engages in developing of small molecules different therapies for neuroscience, inflammation, and immunology indications in the United States. The company's lead asset is PIPE-791, a novel, brain penetrant, small molecule inhibitor of the lysophosphatidic acid 1 receptor (LPA1R) for the treatment of idiopathic pulmonary fibrosis and chronic pain. It also develops PIPE-307, a novel, small-molecule inhibi…
Full company profileContineum Therapeutics, Inc. Class A Common Stock financial statements
2026 annualized: Fiscal year 2026 is not finished. Income statement and cash flow are annualized from 3 quarters up to Sep 30, 2026, the balance sheet is the latest quarter. Figures change when the annual report is published.
Contineum Therapeutics, Inc. Class A Common Stock annual financial statements (USD; K = thousand, M = million, B = billion, T = trillion)
| Item | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 Anlz |
|---|---|---|---|---|---|---|
| Income Statement | ||||||
| Revenue | 0.00 | 0.00 | 50.0M | 0.00 | 0.00 | 0.00 |
| Gross Profit | - | -329K | 50.0M | -258K | -323K | - |
| Operating Income | -28.6M | -22.7M | -16.1M | -50.9M | -68.1M | -73.7M |
| EBITDA | -28.3M | -23.5M | 23.6M | -42.0M | -67.7M | -73.4M |
| Net Income | -29.0M | -24.3M | 22.7M | -42.3M | -60.0M | -64.4M |
| EPS | -1.15 | -0.97 | 0.90 | -1.63 | -2.17 | -1.68 |
| Balance Sheet | ||||||
| Total Assets | 70.5M | 50.6M | 130M | 213M | 277M | 257M |
| Total Liabilities | 8.93M | 11.4M | 198M | 14.8M | 15.7M | 11.6M |
| Shareholders' Equity | 61.6M | 39.3M | -67.9M | 198M | 261M | 245M |
| Cash & Short-term Investments | 69.0M | 47.2M | 125M | 205M | 263M | 244M |
| Total Debt | 4.91M | 5.85M | 193M | 6.26M | 8.25M | 6.27M |
| Cash Flow | ||||||
| Operating Cash Flow | -26.3M | -20.1M | 19.3M | -32.8M | -55.3M | -51.8M |
| Capital Expenditure | 168K | 118K | 414K | 514K | 231K | 424K |
| Free Cash Flow | -26.4M | -20.2M | 18.9M | -33.4M | -55.5M | -52.2M |
| Ratios | ||||||
| ROE | -47.1% | -61.8% | - | -21.3% | -23.0% | -26.2% |
| ROA | -41.1% | -47.9% | 17.4% | -19.9% | -21.7% | -25.1% |
| Net Profit Margin | - | - | 45.4% | - | - | - |
| Debt to Equity | 0.08x | 0.15x | - | 0.03x | 0.03x | 0.03x |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Total Debt
- Short and long-term borrowings.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
- Debt to Equity
- Total debt divided by shareholders' equity.
Contineum Therapeutics, Inc. Class A Common Stock dividends
Contineum Therapeutics, Inc. Class A Common Stock has not paid dividends in the last 5 fiscal years.
Who owns Contineum Therapeutics, Inc. Class A Common Stock
- Insiders 0.06%
- Institutions 99.70%
- Public & others 0.24%
- Shares outstanding 35.4M
- Free float 30.1M
Top funds holding CTNM.US
| Holder | Shares | % of shares | Change | As of |
|---|---|---|---|---|
| Franklin Biotechnology Discv A(acc)USD | 1.10M | 2.81% | 0.00% | Sep 2026 |
| Vanguard MStar Total Stk Mkt Idx Invest | 982K | 2.50% | 0.00% | Sep 2026 |
| iShares Russell 2000 ETF | 698K | 1.78% | 0.00% | Oct 2026 |
| Fidelity Select Pharmaceuticals Port | 614K | 1.56% | 0.00% | Sep 2026 |
| Franklin Biotechnology Discovery A | 601K | 1.53% | 0.00% | Sep 2026 |
| Fidelity Advisor Biotechnology I | 482K | 1.23% | +114.27% | Sep 2026 |
| Fidelity Select Health Care | 450K | 1.15% | 0.00% | Aug 2026 |
| Fidelity Small Cap Index | 297K | 0.76% | +0.82% | Aug 2026 |
| Fidelity Advisor Health Care I | 280K | 0.71% | 0.00% | Sep 2026 |
| iShares Russell 2000 Value ETF | 255K | 0.65% | 0.00% | Oct 2026 |
| Strategic Advisers Fidelity US TtlStk | 245K | 0.62% | 0.00% | Sep 2026 |
| iShares Biotechnology ETF | 233K | 0.59% | -0.19% | Oct 2026 |
| State Street® SPDR® S&P® PhrmctlsETF | 225K | 0.57% | +2.88% | Oct 2026 |
| Vanguard Russell 2000 ETF | 163K | 0.42% | +5.49% | Sep 2026 |
| Schwab US Small-Cap ETF™ | 160K | 0.41% | +0.24% | Oct 2026 |
| Fidelity Extended Market Index | 149K | 0.38% | +14.61% | Sep 2026 |
| Fidelity Small Cap Stock | 133K | 0.34% | -24.58% | Aug 2026 |
| iShares Micro-Cap ETF | 85.1K | 0.22% | 0.00% | Oct 2026 |
| Fidelity VIP Health Care Initial | 80.0K | 0.20% | 0.00% | Sep 2026 |
| Schwab Small Cap Index | 68.2K | 0.17% | +4.59% | Sep 2026 |
Top institutions holding CTNM.US
| Holder | Shares | % of shares | Change | As of |
|---|---|---|---|---|
| Suvretta Capital Management, LLC | 2.84M | 7.24% | 0.00% | Jun 2026 |
| Jupiter Topco LLC | 2.73M | 6.96% | 0.00% | Jun 2026 |
| BlackRock Inc | 2.06M | 5.26% | +208.52% | Jun 2026 |
| Johnson & Johnson | 1.98M | 5.04% | 0.00% | Jun 2026 |
| Franklin Templeton Inc | 1.84M | 4.68% | 0.00% | Jun 2026 |
| Balyasny Asset Management LLC | 1.52M | 3.88% | -9.66% | Jun 2026 |
| Vanguard Capital Management, LLC | 1.32M | 3.37% | +8.83% | Jun 2026 |
| Perceptive Advisors LLC | 1.26M | 3.20% | 0.00% | Jun 2026 |
| FMR Inc | 1.04M | 2.65% | +27.64% | Jun 2026 |
| Millennium Management LLC | 932K | 2.37% | -39.32% | Jun 2026 |
| Great Point Partners LLC | 921K | 2.35% | +15.16% | Jun 2026 |
| Longaeva Partners L.P. | 813K | 2.07% | +11.02% | Jun 2026 |
| Ikarian Capital, LLC | 808K | 2.06% | 0.00% | Jun 2026 |
| Sectoral Asset Management Inc | 728K | 1.85% | 0.00% | Jun 2026 |
| Geode Capital Management, LLC | 693K | 1.77% | +145.78% | Jun 2026 |
| Hillhouse Capital Advisors, Ltd. | 669K | 1.70% | 0.00% | Jun 2026 |
| Red Tree Management, LLC | 638K | 1.63% | 0.00% | Sep 2026 |
| Versant Venture Management LLC | 543K | 1.38% | 0.00% | Jun 2026 |
| The Goldman Sachs Group Inc | 497K | 1.27% | +61.92% | Jun 2026 |
| Boxer Capital Management, LLC | 494K | 1.26% | 0.00% | Jun 2026 |
Contineum Therapeutics, Inc. Class A Common Stock company profile
- Company name
- Contineum Therapeutics, Inc. Class A Common Stock
- Ticker
- CTNM.US
- Exchange
- USA Stocks
- Listed since
- Apr 5, 2024
- Sector
- Healthcare
- Industry
- Pharmaceuticals
- Employees
- 51
- Fiscal year end
- December
- Address
- 3565 General Atomics Court, San Diego, CA, United States, 92121
- Phone
- 858 333 5280
- Website
- contineum-tx.com
About Contineum Therapeutics, Inc. Class A Common Stock
Contineum Therapeutics, Inc., a clinical stage biopharmaceutical company, engages in developing of small molecules different therapies for neuroscience, inflammation, and immunology indications in the United States. The company's lead asset is PIPE-791, a novel, brain penetrant, small molecule inhibitor of the lysophosphatidic acid 1 receptor (LPA1R) for the treatment of idiopathic pulmonary fibrosis and chronic pain. It also develops PIPE-307, a novel, small-molecule inhibitor of the muscarinic type 1 receptor for depression and relapse-remitting multiple sclerosis. The company was formerly known as Pipeline Therapeutics, Inc. and changed its name to Contineum Therapeutics, Inc. in November 2023. Contineum Therapeutics, Inc. was incorporated in 2009 and is based in San Diego, California.
Contineum Therapeutics, Inc. Class A Common Stock management
10- Mr. Carmine N. Stengone MBA, MSPresident, CEO & Director · born 1976
- Mr. Peter T. Slover CPAChief Financial Officer · born 1975
- Dr. Timothy R. Watkins M.D., M.Sc.Chief Medical Officer & Head of Development · born 1974
- Ms. Morgan PaulsenSenior Manager of Accounting
- Dr. Daniel S. Lorrain Ph.D.Chief Science Officer · born 1969
- Mr. Steve E. KunszaboSenior Director of Investor Relations & Corporate Communications
- Mr. John S. HealyGeneral Counsel & Corporate Secretary · born 1972
- Mr. Austin Chen Ph.D.Senior VP & Head of Research
- Ms. Julie S. IwashitaSenior Vice President of Clinical Operations
- Ms. Kristina Haeckl RacSenior Vice President of Regulatory Affairs